(Albany, US) Delveinsight has launched a new report on Complement 3 Glomerulopathy Pipeline
Complement 3 Glomerulopathy Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Complement 3 Glomerulopathy market. A detailed picture of the Complement 3 Glomerulopathy pipeline landscape is provided, which includes the disease overview and Complement 3 Glomerulopathy treatment guidelines. The assessment part of the report embraces in-depth Complement 3 Glomerulopathy commercial assessment and clinical assessment of the Complement 3 Glomerulopathy pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement 3 Glomerulopathy collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Complement 3 glomerulopathy (C3G) was adopted by expert consensus in 2013 to define a group of rare kidneys diseases driven by dysregulation of the complement cascade. It is a type of glomerular disease, characterized by predominant C3 complement component (C3) deposits in the glomeruli in the absence of a significant amount of immunoglobulin and without deposition of C1q and C4. The term C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which are the two patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD appear different from that in C3GN when observed under a microscope. People with DDD generally present at a younger age (childhood or adolescence) compared to people with C3GN (adulthood). In DDD, C3 deposits are bunched up in one area of the glomeruli and appear thick while in case of C3GN, C3 deposits are more spread out and less thick. Progression to end-stage renal disease (ESRD) has been found in 40% of C3G patients, with no detectable difference between those with C3GN versus DDD. Dysregulation of the complement alternative pathway, driven by acquired and/or genetic defects, plays a pathogenetic role in C3G. However, alternative pathway abnormalities are also found in IC-MPGN (immune-complex-MPGN). The most common acquired drivers of C3G are the C3 nephritic factors (C3NeFs),heterogeneous autoantibodies that stabilize the C3 convertase, C3bBb.
Request for free sample page:- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-pipeline-insight
Complement 3 Glomerulopathy Pipeline Development
The report provides insights into:
Complement 3 Glomerulopathy Pipeline
The dynamics of C3G market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapies is expected during the forecast period of 2020-2030..
Emerging drugs included in the report
Scope of the Report
Table of content
1. Report Introduction
2. Complement 3 Glomerulopathy
3. Complement 3 Glomerulopathy Current Treatment Patterns
4. Complement 3 Glomerulopathy – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Complement 3 Glomerulopathy Late Stage Products (Phase-III)
7. Complement 3 Glomerulopathy Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Complement 3 Glomerulopathy Discontinued Products
13. Complement 3 Glomerulopathy Product Profiles
14. Complement 3 Glomerulopathy Key Companies
15. Complement 3 Glomerulopathy Key Products
16. Dormant and Discontinued Products
17. Complement 3 Glomerulopathy Unmet Needs
18. Complement 3 Glomerulopathy Future Perspectives
19. Complement 3 Glomerulopathy Analyst Review
20. Appendix
21. Report Methodology
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/